Therapeutic conundrum: AIDS therapies may be double-edged swords

Neurology

Volumn 74, Issue 16, 2010, Pages 1248-1249

  Clifford, David B ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; COGNITIVE DEFECT; DEMENTIA; DRUG COST; DRUG RESEARCH; EDITORIAL; EPIDEMIC; EUPHORIA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; MEDICAL SPECIALIST; NEUROLOGY; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL;

EID: 77951494175     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181dd4e31     Document Type: Editorial

References (11)

1. Price RW, Brew BJ. The AIDS dementia complex. J Infect Dis 1988;158:1079-1083.
2. Sacktor N, Lyles RH, McFarlane G, et al. HIV-1-related neurological disease incidence changes in the era of highly active antiretroviral therapy. Neurology 1999;52:A252-A253.
3. Tozzi V, Balestra P, Bellagamba R, et al. Persistence of neuropsychologic deficits despite long-term highly active antiretroviral therapy in patients with HIV-related neuro-cognitive impairment: prevalence and risk factors. J Acquir Immune Defic Syndr 2007;45:174-182. (Pubitemid 46869810)
4. Ellis R, Langford D, Masliah E. HIV and antiretroviral therapy in the brain: neuronal injury and repair. Nat Rev Neurosci 2007;8:33-44.
5. Cysique LA, Brew BJ. Neuropsychological functioning and antiretroviral treatment in HIV/AIDS: a review. Neu-ropsychol Rev 2009;19:169-185.
6. Letendre S, Marquie-Beck J, Capparelli E, et al. Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 2008;65:65-70.
7. Eden A, Price RW, Spudich S, Fuchs D, Hagberg L, Gisslen M. Immune activation of the central nervous system is still present after >4 years of effective highly active antiretroviral therapy. J Infect Dis 2007;196:1779-1783.
8. Robertson KR, Su Z, Margolis DM, et al. Neurocognitive effects of treatment interruption in stable HIV-positive patients in an observational cohort. Neurology 2010;74: 1260-1266.
9. Aberg JA, Kaplan JE, Libman H, et al. Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2009 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2009;49:651-681.
10. The Strategies for Management of Antiretroviral Therapy (SMART) Study Group. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006;355: 2283-2296.
11. Feng JY, Johnson AA, Johnson KA, Anderson KS. Insights into the molecular mechanism of mitochondrial toxicity by AIDS drugs. J Biol Chem 2001;276:23832-23837.